Polyclonal catalytic antibodies

Elizabeth L Ostler1, Marina Resmini, Keith Brocklehurst

  • 1Division of Chemistry, School of Pharmacy and Biomolecular Sciences, University of Brighton, Cockcroft Building, Moulsecoomb, Brighton BN2 4GJ, UK.

Polyclonal catalytic antibodies offer advantages in the evaluation of immunogens and in the ease of production of large quantities of antibodies. They comprise the entire immune response of an animal to an immunogen where monoclonals represent a subset. Polyclonal antibodies are consequently particularly suitable for evaluating catalytic antibody responses generated by different haptens or a group of structurally related haptens. The authors reported the first polyclonal catalytic antibodies in 1990. An unexpected finding is that polyclonal catalytic antibodies show single-site kinetic behaviour, i.e. whatever structural heterogeneity exists, the kinetic behaviour is homogeneous. Many groups worldwide have since published work in this area. Three groups are prominent. The authors' group, a group based in Austin, Texas, and led by Iverson, and a Shanghai group. The authors' group works with sheep antibodies and has published mechanistic studies and, more recently, specificity studies that revealed the catalysis of a beta-lactam. Most of this work over a 10-year period was performed by using a single bleed from a single sheep, which gives an indication of the ease of production and utility of such catalytic antibodies. Iverson's group works with rabbit antibodies and has published much work on the evaluation of catalytic antibodies generated by structurally related haptens. The Shanghai group has concentrated on the studies of polyclonal catalytic antibodies for electrocyclic reactions where any danger of contaminating enzymes is reduced. The use of immunisation to generate therapeutically useful catalytic antibodies (necessarily polyclonal) in a host animal is an attractive target. Several groups are working towards this. The authors themselves have published in this area and promising recent studies come from a group working in France on immunisation to protect against nerve agents and a Texas group (based in Houston) that has demonstrated active immunisation to generate antibodies that catalyse the hydrolysis of a carbamate insecticide.

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...